Introduction
============

Behcet's disease (BD) and Vogt--Koyanagi--Harada (VKH) syndrome have been proven as two of the most common and severe sight-threatening uveitis entities in China \[[@r1],[@r2]\]. BD is a chronic, multisystem inflammatory disorder characterized by recurrent oral ulcerations, genital ulcerations, recurrent uveitis, and multiple skin lesions \[[@r3]\]. Similar to BD, VKH syndrome is a chronic, multisystem autoimmune disease characterized by bilateral granulomatous panuveitispoliosis, vitiligo, alopecia, and central nervous system and auditory signs \[[@r4]\]. So far, the prevalence of BD or VKH syndrome in China is unclear. Usually, the syndrome occurs more frequently in Turks, Chinese Han, and Japanese individuals, and it is uncommon in Caucasians. Turkey has the highest prevalence rate of BD (80--420 cases per 100,000 persons), whereas the disease is rare in Caucasian (0.27--7.5 cases per 100,000 persons) \[[@r5],[@r6]\]. Although the pathogenesis of the two diseases remains unclear, it is currently thought a genetic predisposition coupled with a triggering event may play a pivotal role in its development \[[@r7],[@r8]\]. Genetic predisposition is an important element, as evidenced by a strong association with the human leukocyte antigen (HLA) system \[[@r9]-[@r11]\]. More recently, studies have reported the association of many non-HLA genes with the two diseases, such as endoplasmic reticulum aminopeptidase 1 (ERAP1), killer cell lectin-like receptor subfamily C, member 4 (KLRC4), chemokine receptor 1 (CCR1), signal transducer and activator of transcription-4 (STAT4) \[[@r12]-[@r14]\], interleukin (IL)-2, IL-4, IL23R \[[@r15]\], transforming growth factor (TGF)-beta \[[@r16]\], tumor necrosis factor (TNF)-alpha \[[@r17]\], tumor necrosis factor alpha-induced pro3 (TNFAIP3) \[[@r18]\], and the small ubiquitin-like modifier 4 (SUMO4) \[[@r19]\] gene for BD, as well as IL23R-C1orf141 \[[@r20]\], ZNF365-ADO-EGR2 \[[@r20]\], CTLA-4, and the IL-17 gene for VKH syndrome \[[@r21]-[@r23]\]. As many of the proteins involved in the immune response appear to be polymorphic, it can be expected many more gene polymorphisms related to the immune system and its mediators will be identified in the predisposition of inflammatory diseases, such as BD and VKH syndrome.

IL-10, an anti-inflammatory cytokine, is produced by T lymphocytes (mainly Th2 subsets), B lymphocytes, NK cells, mast cells, eosinophils, dendritic cells, monocytes, and macrophages \[[@r24]\]. IL-10 was demonstrated to be an important cytokine-suppressing autoimmunity and inflammatory response \[[@r25]-[@r28]\]. IL-10 inhibits antigen-presenting cells by downregulating the cell surface expression of HLA molecules \[[@r29]\]. Moreover, it inhibits T cell function by suppressing the expressions of proinflammatory cytokines, such as TNFα, IL-1, IL-6, IL-8, and IL-12 \[[@r30],[@r31]\]. In addition to these inhibitory actions, IL-10 inhibits naïve T cell differentiation into T helper 17 cells (Th17), as well as promotes the differentiation of CD4(+)CD25(-) T cells into regulatory T cells (Tregs) \[[@r32]\]. Gene polymorphisms of IL10 were associated with several immune-related disorders, including Crohn's disease (CD) \[[@r33]\], type 2 diabetes \[[@r34]\], systemic sclerosis \[[@r35]\], Sjogren's syndrome \[[@r36]\], and Graves' disease \[[@r37]\]. Several studies from Iran, Japan, and Turkey have also identified IL-10 as a risk gene for BD \[[@r38]-[@r40]\]. These studies have not yet been confirmed in China and we therefore performed a two-stage association study to examine whether IL-10 polymorphisms might also increase the susceptibility of BD and VKH syndrome in our population. We found the IL-10 gene was associated with BD in Chinese Han and in view of the independent confirmation by various independent groups, one may conclude IL-10 definitely plays a role in the pathogenesis of this disease. On the other hand, IL-10 does not seem to be a susceptibility gene for VKH syndrome.

Methods
=======

Subjects
--------

The first-stage study cohort comprised 300 BD patients, 300 VKH syndrome patients, and 350 normal controls. As well, 418 BD patients and 1,403 normal controls were enrolled in the second stage ([Table 1](#t1){ref-type="table"}). All subjects were Chinese Han. The patients were continuously diagnosed at the Zhongshan Ophthalmic Center, Sun Yat-sen University, or the First Affiliated Hospital of Chongqing Medical University, China between April 2005 and November 2012. The diagnosis of BD was strictly based on the criteria of the International Study Group of BD \[[@r41]\]. The clinical characteristics of BD cases were assessed at the time of diagnosis and are summarized in [Table 2](#t2){ref-type="table"}. The normal controls consisted of spouses of the patients or accompanying people who had no genetic connection to the patients. This study was approved by the ethics committee of the First Affiliated Hospital of Chongqing Medical University, China. Every investigated subject provided informed consent before the collection of blood. The study was in agreement with the ethical principles described in the Declaration of Helsinki.

###### Summary characteristic of Behcet's patients and normal control subjects in this study.

  **Analysis**   **Case**   **Control**                                 
  -------------- ---------- ------------- -------- ------ ------------- ----------
  StageI         300        33.52±8.73    257/43   350    36.57±10.89   217/133
  Stage II       418        33.66±8.83    362/56   1403   40.44±11.14   789/614
  Combined       718        33.60±8.78    619/99   1753   39.66±11.19   1006/747

SD, standard deviation

###### The number and ratio of Behcet's patients with clinical features.

  **Clinical features**                       **BD patients**   
  ----------------------------- ------------------------------- ------
  Female                        99                              13.8
  Male                          619                             86.2
  Age at onset (years \[SD\])   33.60 (8.78)                     
  Uveitis                       718                             100
  Genital ulcers                413                             57.5
  Skin lesions                  538                             74.9
  Hypopyon                      188                             26.2
  Arthritis                     99                              15.2
  Prick tests                   164                             22.8

SD, standard deviation

DNA extraction
--------------

Blood samples were collected in EDTA tubes and stored at −80 °C until use. Genomic DNA was extracted from the peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions.

SNP genotyping
--------------

The genotypes of [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871), [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872),[rs1800896](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800896), [rs3021094](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094), [rs3790622](http://www.ncbi.nlm.nih.gov/snp/?term=rs3790622) were examined by PCR-restricted fragment length polymorphism (PCR-RFLP). The target DNA sequence was amplified by the PCR method with proper primers for each single nucleotide polymorphism (SNP; [Table 3](#t3){ref-type="table"}). Each PCR was performed in a 7-µl reaction mixture containing 3.5 µl Premix Taq (Promega, Madison), 2 µl water, 0.5 pmol primers, and 0.2 µg genomic DNA for amplification of the DNA. The PCR conditions were as follows: initial denaturation at 95 °C for 5 min followed by 40 cycles of denaturation at 95 °C for 30 s, annealing at different temperatures (60 °C for [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871), 59 °C for [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872), 56 °C for [rs1800896](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800896), 55 °C for [rs3021094](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094), and 60 °C for [rs3790622](http://www.ncbi.nlm.nih.gov/snp/?term=rs3790622)) for 30 s, extension at 72 °C for 30 s, and a final extension at 72 °C for 5 min. PCR products were respectively digested with 2.5 U of EcoRV, Csp6I, BslI, BglI, and TasI (Fermentas, MBI) for 10--16 h. After digestion, PCR products were visualized on agarose gels at an appropriate concentration. The frequency of a given genotype was estimated by direct counting. In addition, rs1554286 was genotyped by the TaqMan genotyping assay (Applied Biosystems, Foster City, CA) on the 7500 real-time PCR system (Applied Biosystems), according to the supplier manual. Details of the TaqMan assay are listed in [Table 3](#t3){ref-type="table"}. A genotype analysis was performed using TaqMan® Genotyper Software. To confirm the accuracy of the two methods used, we randomly selected 20% of the samples to undergo direct sequencing to validate the results of genotyping by PCR-RFLP and TaqMan (Beijing Liuhe BGI Inc.).

###### The details of primers of IL10 SNPs, restriction enzymes used for RFLP analysis and assay information from Applied Biosystems for TaqMan SNP assays analysis.

  **rs number**                                                  **details**                                                                 
  -------------------------------------------------------------- ---------------------------- ---------------------------------------------- -------
  [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871)   Primers/Restriction enzyme   5′ TGTACCCTTGTACAGGTGATGTGA 3′                 EcoRV
                                                                                              5′ ACCCCGATTTCATTAGGATTCT 3′                    
  [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872)   Primers/Restriction enzyme   5′ GAGAATCCTAATGAAATCGGG 3′                    Csp6I
                                                                                              5′ TTGCTAACTTAGGCAGTCACC 3′                     
  [rs1800896](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800896)   Primers/Restriction enzyme   5′ CAAGACAACACTACTAAGGCTCC 3′                  BslI
                                                                                              5′ CAGCACATAGAATGAAACCTTG 3′                    
  [rs3021094](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094)   Primers/Restriction enzyme   5′CGGCCAGATTTTTTAAATAACTTGCCTCTG3′             BglI
                                                                                              5′ TGAAATGCGGTCTTTTTGATGCCCT 3′                 
  [rs3790622](http://www.ncbi.nlm.nih.gov/snp/?term=rs3790622)   Primers/Restriction enzyme   5′ TGCTTAGAGCGTTTCCAGACC 3′                    TasI
                                                                                              5′ TTTCTGCGGAGCTACATTCG 3′                      
  [rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286)   ABI assay ID                 C\_\_\_8828812_10                               
                                                                 SNP type                     Transition, Substitution, Intron, Intragenic    
                                                                 Assay Type                   Validated                                       
                                                                 Chr site                     Chr.1: 206,944,233                              

Cell isolation and culture
--------------------------

The healthy study subjects used for the IL-10 gene expression assays were the partners of the patients or an accompanying person, totaling 18 individuals. Peripheral blood samples were obtained using vacuum tubes containing EDTA. Before the isolation of peripheral blood mononuclear cells (PBMCs), 1 ml of peripheral blood was stored in 1.5-ml EDTA tubes for genotyping. PBMCs were isolated from heparinized blood samples by Ficoll--Hypaque density-gradient centrifugation. Isolated PBMCs (2×10**^6^** cells per well) were seeded in 24-well plates and cultured in an RPMI medium 1640 supplemented with 10% fetal calf serum (FCS, Greiner, Wemmel, Belgium), 100 U/ml penicillin, and 100 µg/ml streptomycin. To detect IL-10 production, PBMCs were stimulated with a mix of the anti-CD3 antibody (5 µg/ml, eBioscience, San Diego, CA) and anti-CD28 antibody (1 µg/ml, eBioscience) for 72 h, or 100 ng/ml of lipopolysaccharide (LPS, 100 ng/ml; Sigma, MO) for 24 h.

DNA extraction, RNA extraction, and cDNA synthesis
--------------------------------------------------

DNA was extracted from whole blood using the QIAamp DNA Blood Mini Kit (Qiagen). Total RNA was extracted from PBMCs using TRIzol (Invitrogen, San Diego, CA), followed by reverse transcription using a transcriptase kit (Applied Biosystems, ABI).

Genotyping and RT-PCR
---------------------

The genotype of rs1800871 was examined by PCR-RFLP, as mentioned above. Real-time quantitative PCR was performed using the Applied Biosystems 7500 System (Applied Biosystems) to quantify IL-10 mRNA transcripts. The relative expression level of IL-10 mRNA was normalized by the expression of β-actin mRNA in each sample. Real-time RT-PCR primers were as follows: for IL-10 transcripts, 5′AAGACCCAGACATCAAGGCG3′ (forward) and 5′AATCGATGACAGCGCCGTAG3′ (reverse), and for β-actin, 5′GGATGCAGAAGGAGATCACTG3′ (forward) and 5′CGATCCACACGGAGTACTTG3′ (reverse). Relative expression levels were calculated using the 2**^---ΔΔCt^** method.

Statistical analysis
--------------------

For each SNP, a deviation of genotype frequencies in controls from the Hardy--Weinberg equilibrium (HWE) was assessed using the chi-square test. No SNPs showed any significant deviation from the HWE (p\>0.05). To ensure the accuracy of the genotyping of six SNPs in the investigated subjects, we compared the patterns of linkage disequilibrium (LD) of the six SNPs included in the study. Allele frequencies, genotype frequencies, HWE, and LD were calculated using the online platform [SHEsis](http://analysis.bio-x.cn) \[[@r42]\]. Allele and genotype frequencies were compared between patients and controls by the chi-square test. Risks were evaluated by odds ratios (ORs) with 95% confidence intervals (CIs). The expression of mRNA was analyzed by an independent samples *t* test. Data were analyzed using SPSS version 16.0 (Chicago, IL). P values were corrected (*P*~corrected~(*P*~corr~)) for multiple comparisons with the Bonferroni correction by multiplying with the number of analyses performed, and *P*~corr~\<0.05 was considered statistically significant.

Results
=======

First-stage study for IL-10 in BD and VKH syndrome
--------------------------------------------------

Six SNPs, including [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871), [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872),[rs1800896](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800896), [rs3021094](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094), [rs3790622](http://www.ncbi.nlm.nih.gov/snp/?term=rs3790622), and [rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286), were successfully genotyped in 300 BD patients, 300 VKH syndrome patients, and 350 healthy controls. The distribution of genotype and allele frequencies of the six SNPs did not deviate from the HWE in the controls.

The frequency of the T allele of [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) was obviously higher in BD patients than in the controls (p = 1.01×10^−6^, *P*~corr~ = 1.82×10^−5^, OR = 1.837, 95%CI = 1.437--2.347), whereas the CC genotype frequency was significantly lower in BD patients (p = 4.6×10^−7^, *P*~corr~ = 8.28×10^−6^, OR = 0.142, 95%CI = 0.060--0.338). Similar to [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871), the frequencies of the C allele of [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872) (p = 3.39×10^−6^, *P*~corr~ = 6.1×10^−5^, OR = 0.562, 95%CI = 0.440--0.717) and the C allele of [rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286) (p = 1.75×10^−6^, *P*~corr~ = 3.15×10^−5^, OR = 0.558, 95%CI = 0.438--0.709) were lower in BD patients than in healthy controls. Alternatively, the frequencies of the AA genotype of [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872) (p = 2.22×10^−5^, *P*~corr~ = 4.0×10^−4^, OR = 1.962, 95%CI = 1.435--2.682) and the TT genotype of [rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286) (p = 1.51×10^−6^, *P*~corr~ = 2.72×10^−5^, OR = 2.154, 95%CI = 1.572--2.950) were distinctly higher in BD patients. There was no statistically significant difference concerning the genotypes and alleles of the other three SNPs between patients with BD and the controls ([Table 4](#t4){ref-type="table"}). The result showed there were no differences in the allele and genotype frequencies of the six SNPs between VKH syndrome patients and controls ([Table 5](#t5){ref-type="table"}).

###### Genotype and allele frequencies of IL10 polymorphisms in BD patients and controls.

  **SNPs**                                                       **study**     **Allele**      **Case**     **Control**    **P value**           **Pc value**          **OR(95%CI)**
  -------------------------------------------------------------- ------------- ------------- -------------- -------------- --------------------- --------------------- ---------------------
  [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871)   StageI        C C           6(0.020)       44(0.126)      4.60×10^−7^           8.28×10^−6^           0.142(0.060--0.338)
  C T                                                            126(0.420)    160(0.457)    0.342          NS             0.860(0.630--1.174)                         
  T T                                                            168(0.560)    146(0.417)    2.80×10^−4^    5.03×10^−3^    1.778(1.302--2.429)                         
  C                                                              138(0.230)    248(0.354)    1.01×10^−6^    1.82×10^−5^    0.544(0.426--0.696)                         
  T                                                              462(0.770)    452(0.646)    1.01×10^−6^    1.82×10^−5^    1.837(1.437--2.347)                         
  StageII                                                        C C           27(0.065)     166(0.118)     0.002          0.03                  0.515(0.337--0.785)   
  C T                                                            175(0.419)    679(0.484)    0.019          NS             0.768(0.616--0.958)                         
  T T                                                            216(0.517)    558(0.398)    1.55×10^−5^    2.33×10^−4^    1.619(1.300--2.017)                         
  C                                                              229(0.274)    1011(0.360)   3.73×10^−6^    5.59×10^−5^    0.670(0.565--0.794)                         
  T                                                              607(0.726)    1795(0.640)   3.73×10^−6^    5.59×10^−5^    1.493(1.259--1.770)                         
  Combined                                                       C C           33(0.046)     210(0.120)     2.19×10^−8^    3.95×10^−7^           0.354(0.243--0.517)   
  C T                                                            301(0.419)    839(0.479)    0.007          NS             0.786(0.660--0.937)                         
  T T                                                            384(0.535)    704(0.402)    1.39×10^−9^    2.50×10^−8^    1.713(1.438--2.041)                         
  C                                                              367(0.256)    1259(0.359)   2.03×10^−12^   3.65×10^−11^   0.613(0.534--0.703)                         
  T                                                              1069(0.744)   2247(0.641)   2.03×10^−12^   3.65×10^−11^   1.632(1.423--1.872)                         
  [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872)   StageI        A A           170(0.567)     140(0.400)     2.22×10^−5^           4×10^−4^              1.962(1.435--2.682)
                                                                 A C           120(0.400)    174(0.497)     0.013          NS                    0.674(0.494--0.921)   
                                                                 C C           10(0.033)     36(0.103)      0.001          0.018                 0.301(0.147--0.617)   
                                                                 A             460(0.767)    454(0.649)     3.39×10^−6^    6.1×10^−5^            1.780(1.394--2.274)   
                                                                 C             140(0.233)    246(0.351)     3.39×10^−6^    6.1×10^−5^            0.562(0.440--0.717)   
  [rs1800896](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800896)   StageI        A A           271(0.903)     293(0.837)     0.013                 NS                    1.818(1.129--2.928)
                                                                 A G           29(0.097)     56(0.160)      0.017          NS                    0.562(0.348--0.906)   
                                                                 G G           0(0.000)      1(0.003)       0.354          NS                                          
                                                                 A             57(0.952)     642(0.917)     0.013          NS                    1.779(1.123--2.817)   
                                                                 G             29(0.048)     58(0.083)      0.013          NS                    0.562(0.355--0.890)   
  [rs3021094](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094)   StageI        A A           58(0.193)      100(0.286)     0.006                 NS                    0.599(0.414--0.866)
                                                                 A C           173(0.577)    199(0.569)     0.835          NS                    1.034(0.757--1.412)   
                                                                 C C           69(0.230)     51(0.146)      0.006          NS                    1.751(1.173--2.614)   
                                                                 A             289(0.482)    399(0.570)     0.001          0.018                 0.701(0.563--0.873)   
                                                                 C             311(0.518)    301(0.430)     0.001          0.018                 1.426(1.146--1.776)   
  [rs3790622](http://www.ncbi.nlm.nih.gov/snp/?term=rs3790622)   StageI        C C           260(0.867)     312(0.891      0.333                 NS                    0.792(0.493--1.271)
                                                                 C T           39(0.130)     38(0.109)      0.399          NS                    1.227(0.762--1.975)   
                                                                 T T           1(0.003)      0(0.000)       0.280          NS                                          
                                                                 C             559(0.932)    662(0.946)     0.291          NS                    O.783(0.496--1.234)   
                                                                 T             41(0.068)     38(0.054)      0.291          NS                    1.278(0.810--2.015)   
  [rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286)   StageI        T T           168(0.560)     130(0.371)     1.51×10^−6^           2.72×10^−5^           2.154(1.572--2.950)
                                                                 C T           116(0.387)    181(0.517)     8.72×10^−4^    0.015687              0.589(0.430--0.805)   
                                                                 C C           16(0.053)     39(0.111)      0.080          NS                    0.449(0.246--0.822)   
                                                                 T             452(0.753)    441(0.630)     1.75×10^−6^    3.15×10^−5^           1.794(1.410--2.282)   
                                                                 C             148(0.247)    259(0.370)     1.75×10^−6^    3.15×10^−5^           0.558(0.438--0.709)   

OR, odds ratio; Pc, Bonferroni corrected p value; SNP, single-nucleotide polymorphisms; NS, not significant

###### The first-stage study Genotype and allele frequencies of IL10 polymorphisms in Han Chinese VKH syndrome patients and healthy controls.

  **SNPs**                                                       **Allele**   **Case**     **Control**   **P value**   **Pc value**            **OR(95%CI)**
  -------------------------------------------------------------- ------------ ------------ ------------- ------------- ----------------------- ---------------------
  [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871)   C C          28(0.093)    44(0.126)     0.190         NS                      0.716(0.434--1.182)
  C T                                                            138(0.460)   160(0.457)   0.942         NS            1.012(0.742--1.378)     
  T T                                                            134(0.447)   146(0.417)   0.449         NS            1.128(0.826--1.540)     
  C                                                              194(0.323)   248(0.354)   0.240         NS            0.871(0.691--1.097)     
  T                                                              406(0.677)   452(0.646)   0.240         NS            1.148(0.912--1.446)     
  [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872)   A A          120(0.400)   140(0.400)    1             NS                      1.000(0.730--1.370)
  A C                                                            160(0.533)   174(0.497)   0.357         NS            1.156(0.849--1.574)     
  C C                                                            20(0.067)    36(0.103)    0.101         NS            0.623(0.352--1.101)     
  A                                                              400(0.667)   454(0.649)   0.493         NS            1.084(0.861--1.364)     
  C                                                              200(0.333)   246(0.351)   0.493         NS            0.923(0.733--1.161)     
  [rs1800896](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094)   A A          252(0.840)   293(0.837)    0.921         NS                      1.021(0.672--1.553)
  A G                                                            48(0.160)    56(0.160)    1             NS            1.000(0.657--1.523)     
  G G                                                            0(0.000)     1(0.003)     0.354         NS                                    
  A                                                              552(0.920)   642(0.917)   0.851         NS            1.039(0.697--1.548)     
  G                                                              48(0.080)    58(0.083)    0.851         NS            0.963(0.646--1.434)     
  [rs3021094](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094)   A A          76(0.253)    100(0.286)    0.354         NS                      0.848(0.599--1.202)
  A C                                                            170(0.567)   199(0.569)   0.961         NS            0.992(0.727--1.355)     
  C C                                                            54(0.180)    51(0.146)    0.236         NS            1.287(0.847--1.955)     
  A                                                              322(0.537)   399(0.570)   0.228         NS            0.874(0.702--1.088)     
  C                                                              278(0.463)   301(0.430)   0.228         NS            1.144(0.919--1.425)     
  [rs3790622](http://www.ncbi.nlm.nih.gov/snp/?term=rs3790622)   C C          276(0.920)   312(0.891)    0.216         NS                      1.401(0.819--2.394)
  C T                                                            24(0.080)    38(0.109)    0.216         NS            0.714(0.418--1.220)     
  T T                                                                                                    NS                                    
  C                                                              576(0.960)   662(0.946)   0.228         NS            1.378(0.817--2.324)     
  T                                                              24(0.040)    38(0.054)    0.228         NS            0.726(0.0.430--1.225)   
  [rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286)   T T          124(0.413)   130(0.371)    0.275         NS                      1.192(0.869--1.635)
  C T                                                            150(0.500)   181(0.517)   0.663         NS            0.934(0.686--1.271)     
  C C                                                            26(0.087)    39(0.111)    0.294         NS            0.757(0.449--1.275)     
  T                                                              398(0.663)   441(0.630)   0.210         NS            1.157(0.921--1.454)     
  C                                                              202(0.337)   259(0.370)   0.210         NS            0.864(0.689--1.086)     

OR, odds ratio; Pc, Bonferroni corrected p value; SNP, single-nucleotide polymorphisms; NS, not significant

Second-stage and combined study for IL-10 in Behcet's disease
-------------------------------------------------------------

The LD analysis showed the patterns of the SNPs [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871), [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872), [rs3021094](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094), and [rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286) were strongly linked ([Figure 1](#f1){ref-type="fig"}). In addition, the p value of [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) was the smallest among the aforementioned three positive SNPs in the first-stage study ([Table 4](#t4){ref-type="table"}). Therefore, we chose [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) to conduct a replication study in an independent cohort including an additional set of 418 BD patients and 1,403 normal controls to confirm further the findings of the first-stage study.

![The relative positions of the investigated SNPs and the LD analysis of the examined SNPs of IL-10. **A**: The relative positions of the investigated SNPs of IL10 tested in this study (red arrows). **B**: An LD analysis was performed for SNPs [rs1800896](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800896), [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871), [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872), [rs3790622](http://www.ncbi.nlm.nih.gov/snp/?term=rs3790622), [rs3021094](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094), and [rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286) based on our data using Haploview software version 4.2. The number in the square indicates r^2^ value.](mv-v21-589-f1){#f1}

The second-stage study showed the frequency of the T allele of [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) was significantly higher in BD patients than in controls (p = 3.73×10^−6^, *P*~corr~ = 5.59×10^−5^, OR = 1.493, 95%CI = 1.259--1.770). Combining the data of the first-stage and second-stage studies showed that rs1800871 was convincingly associated with a susceptibility to BD (p = 2.03×10^−12^, *P*~corr~ = 3.65×10^−11^, OR = 1.632, 95%CI = 1.423--1.872; [Table 4](#t4){ref-type="table"}).

When the genotype and allele frequencies were analyzed according to the clinical features, the results showed significantly higher frequencies of the [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) T allele in BD patients with extraocular findings, including genital ulcers, skin lesions, and a positive pathergy test, as compared to that observed in healthy controls. There was no difference between BD patients with arthritis and healthy controls ([Table 6](#t6){ref-type="table"}).

###### The combined study genotype and allele frequencies of [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) in BD patients and controls according to the Clinical features.

  **SNPs**                 **Allele**   **Case**      **Control**    **P value**   **Pc value**          **OR(95%CI)**
  ------------------------ ------------ ------------- -------------- ------------- --------------------- ---------------------
  Genital ulcers           C C          19(0.046)     210(0.120)     1.15×10^−5^   1.38×10^−4^           0.354(0.219--0.574)
  C T                      17(0.431)    839(0.479)    0.081          NS            0.825(0.665--1.024)   
  T T                      21(0.523)    704(0.402)    7.11×10^−6^    8.53×10^−5^   1.634(1.317--2.026)   
  C                        21(0.262)    1259(0.359)   1.01×10^−7^    1.21×10^−6^   0.632(0.533--0.749)   
  T                        61(0.738)    2247(0.641)   1.01×10^−7^    1.21×10^−6^   1.582(1.335--1.875)   
  Skin lesions             C C          28(0.052)     210(0.120)     6.63×10^−6^   7.96×10^−5^           0.403(0.269--0.606)
  C T                      21(0.405)    839(0.479)    0.003          0.036         0.742(0.610--0.903)   
  T T                      29(0.543)    704(0.402)    7.59×10^−9^    9.11×10^−8^   1.769(1.456--2.149)   
  C                        27(0.255)    1259(0.359)   2.13×10^−10^   2.56×10^−9^   0.610(0.523--0.711)   
  T                        80(0.745)    2247(0.641)   2.13×10^−10^   2.56×10^−9^   1.640(1.407--1.912)   
  Arthritis                C C          7(0.071)      210(0.120)     0.14          NS                    0.559(0.256--1.222)
  C T                      47(0.475)    839(0.479)    0.94           NS            0.985(0.656--1.477)   
  T T                      45(0.454)    704(0.402)    0.296          NS            1.242(0.827--1.865)   
  C                        61(0.308)    1259(0.359)   0.145          NS            0.795(0.583--1.083)   
  T                        137(0.692)   2247(0.641)   0.145          NS            1.258(0.923--1.715)   
  Positive pathergy test   C C          5(0.030)      210(0.120)     0.001         0.012                 0.231(0.094--0.569)
  C T                      71(0.433)    839(0.479)    0.263          NS            0.832(0.602--1.149)   
  T T                      88(0.537)    704(0.402)    0.001          0.012         1.725(1.251--2.379)   
  C                        81(0.247)    1259(0.359)   4.63×10^−5^    5.56×10^−4^   0.585(0.451--0.759)   
  T                        247(0.753)   2247(0.641)   4.63×10^−5^    5.56×10^−4^   1.709(1.317--2.216)   

OR, odds ratio; Pc, Bonferroni corrected p value; SNP, single-nucleotide polymorphisms; NS, not significant

Haplotype analysis of IL-10 SNPs and Behcet's disease
-----------------------------------------------------

An LD analysis was performed for six SNPs, including [rs1800896](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800896), [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871), [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872), [rs3790622](http://www.ncbi.nlm.nih.gov/snp/?term=rs3790622), [rs3021094](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094), [rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286), based on our data using Haploview software version 4.2. The results showed that haplotype GACCCA constructed by SNPs[rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286), [rs3021094](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094), [rs3790622](http://www.ncbi.nlm.nih.gov/snp/?term=rs3790622), [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872), [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871), and [rs1800896](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800896) was strongly associated with BD (p = 1.76×10^−7^; [Table 7](#t7){ref-type="table"}).

###### Haplotype results for IL10 SNPs including [rs1800896](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800896),[rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871), [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872), [rs3790622](http://www.ncbi.nlm.nih.gov/snp/?term=rs3790622), [rs3021094](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094), [rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286).

  Block        Case, Control (%)   Chi Square   P Value
  ------------ ------------------- ------------ -----------------
  ACCATA       0.397, 0.337        5.191        0.023
  AACATA       0.228, 0.205        0.999        0.318
  **GACCCA**   0.138, 0.253        27.279       **1.76×10^−7^**
  GACCCG       0.035, 0.070        7.83         0.0051
  ACTATA       0.056, 0.051        0.175        0.675
  GACATA       0.034, 0.025        1.164        0.281
  ACCCTA       0.033, 0.011        8.347        0.0039
  ACCACA       0.013, 0.010        0.348        0.555

Meta-analysis of three IL-10 SNPs in the Chinese Han population
---------------------------------------------------------------

Recently, Wu et al. reported the association of IL-10 SNPs with BD \[[@r43]\]. In that study, the patients were recruited from the department of rheumatology, and only 28.5% patients had ocular manifestations. In our study, the BD patients were recruited from the department of ophthalmology and 100% of patients had uveitis. Wu et al.'s study included four candidate SNPs, namely [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871), [rs1518111](http://www.ncbi.nlm.nih.gov/snp/?term=rs1518111), [rs3021094](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094), and [rs3790622](http://www.ncbi.nlm.nih.gov/snp/?term=rs3790622). As [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) was in a strong LD with[rs1518111](http://www.ncbi.nlm.nih.gov/snp/?term=rs1518111), the remaining three SNPs were included in our study. To understand better the association of IL-10 gene polymorphisms and BD in Chinese Han, a meta-analysis was conducted and the results showed [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) and [rs3790622](http://www.ncbi.nlm.nih.gov/snp/?term=rs3790622) were associated with BD, which is consistent with our study, whereas [rs3021094](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094) shows a discrepancy with our study ([Figure 2](#f2){ref-type="fig"}). Further studies using larger samples are needed to address the inconsistent result.

![Forest plots illustrate the association between IL-10 gene polymorphisms and BD in Chinese Han. For each study, the odds ratio (OR) and 95% confidence interval (CI) values are indicted. The size of each box is proportional to the weight of each study. The squares and horizontal lines correspond to the OR and 95% CI, and the diamond represents the summary OR and 95% CI. A: The [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) T allele versus C allele. **B**: The [rs3021094](http://www.ncbi.nlm.nih.gov/snp/?term=rs3021094) A allele versus C allele. **C**: The [rs3790622](http://www.ncbi.nlm.nih.gov/snp/?term=rs3790622) T allele versus C allele.](mv-v21-589-f2){#f2}

Expression of IL-10 in the PBMCs of controls
--------------------------------------------

The effect of the genotype on the IL-10 mRNA expression was tested in 18 normal genotyped subjects. We tested two individuals with rs1800871 CC, eight individuals with CT, and eight individuals with the TT genotype. After stimulation with LPS, no difference was found concerning the IL-10 mRNA expression by PBMCs in normal controls with different genotypes ([Figure 3](#f3){ref-type="fig"}). Following anti-CD3 and anti-CD28 stimulation, a similar trend was evident ([Figure 3](#f3){ref-type="fig"}).

![The expression of different genotypes of rs1800871/IL-10 at mRNA level in a stimulated condition by LPS or anti-CD3/CD28 antibodies. **A**: The relative expression of IL-10 mRNA in LPS-stimulated PBMCs obtained from healthy controls with the known IL-10 [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) genotype. **B**: The relative expression of IL-10 mRNA by anti-CD3/CD28 antibody-stimulated PBMCs obtained from healthy controls with the known IL-10 [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) genotype. The y-axis represents the IL-10 mRNA relative expression level through the real-time PCR of each genotype. Data are shown as mean ± SD. PBMCs included lymphocytes, such as T, B, and NK cells (90--95%), monocytes (3%), and Dendritic cells.](mv-v21-589-f3){#f3}

Discussion
==========

This study aimed to investigate the association of six SNPs of IL-10 with two uveitis entities, BD and VKH, in the Chinese Han population. The results showed three IL-10 SNPs, including [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871), [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872), and [rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286), were significantly associated with BD, but not with VKH syndrome. These three SNPs are in a strong LD with each other, and the IL-10 [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) (−819 C/T) is considered a functional promoter gene. Our findings are in agreement with earlier studies demonstrating a genetic predisposition of certain IL-10 gene polymorphisms and BD in Iranian, Turkish, and Japanese cohorts \[[@r38]-[@r40]\]. In these latter studies, an association was found with the SNPs [rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286), [rs1518111](http://www.ncbi.nlm.nih.gov/snp/?term=rs1518111), [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871), and [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872).

Further stratification of samples according to clinical features showed [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) was significantly associated with extraocular findings in our BD patients, including genital ulcers, skin lesions, and a positive pathergy test. No significant association was observed in the group of patients manifesting arthritis. Earlier studies on the analysis of disease outcome showed an association between IL-10 [rs1800896](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800896) AA homozygosity and poor outcomes in patients with intermediate uveitis \[[@r44]\]. We also included the SNP rs1800896 in our study but did not find a significant association with BD.

Animal models of experimental uveitis have shown IL-10 plays a protective role in the development of uveitis \[[@r45],[@r46]\]. The role of IL-10 in BD is not yet exactly known, although lower levels of IL-10 were found in the aqueous humor of BD patients as compared to other uveitis entities, which indicated the BD intraocular microenvironment lacks immunosuppressive conditions \[[@r47]\]. As of yet, no data have been published concerning IL-10 plasma levels in BD patients.

The choice of IL-10 gene candidate SNPs was based on the associations reported for other autoimmune diseases \[[@r33]-[@r37]\]. A study on a Turkish cohort of BD patients identified an association of IL10 [rs1518111](http://www.ncbi.nlm.nih.gov/snp/?term=rs1518111) with a p value of 1.88×10^−8^ \[[@r40]\]. We did not use IL-10 [rs1518111](http://www.ncbi.nlm.nih.gov/snp/?term=rs1518111) in our study, but it is in a strong LD with [rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286), which was one of the SNPs we used \[[@r38]\]. An association study on patients with white dot syndrome showed IL-10 [rs2222202](http://www.ncbi.nlm.nih.gov/snp/?term=rs2222202) was associated with multifocal choroiditis with panuveitis with a corrected p value of \<0.012, but not in patients with punctate inner choroidopathy \[[@r48]\]. The SNP [rs2222202](http://www.ncbi.nlm.nih.gov/snp/?term=rs2222202) is linked with the SNP [rs1800896](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800896) in Chinese Han (D' = 1.0, r^2^ = 0.33), and we therefore chose to test the association of SNP [rs1800896](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800896) with BD.

The three SNPs, including [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871), [rs1800872](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800872), and [rs1554286](http://www.ncbi.nlm.nih.gov/snp/?term=rs1554286), showing an association in our study are in a strong LD with each other. In addition, the p value of [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) was the smallest of the aforementioned three positive SNPs in the first-stage study. We therefore focused on [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) in the second part of our study.

A recent study on IL-10 gene polymorphisms (including [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871)) in uveitis patients from Austria did not identify a significant association in cases with HLA-B27-associated anterior uveitis or with intermediate uveitis \[[@r49]\]. The discrepancy with the association we found for this SNP in BD may be due to disease heterogeneity among different uveitis entities. The SNP [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) is located in the 5′UTR region of IL-10, implying a functional role that regulates its gene expression. An expression analysis did not, however, reveal a significant association between genotype and the IL-10 mRNA expression. We did not include patients in the expression analysis due to confounding factors, such as disease activity and variable immunosuppressive treatment regimens. Our results agree with previous reports that also did not observe significant differences in the levels of IL-10 mRNA among healthy controls with different genotypes of [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) \[[@r36]\]. Nonetheless, they did observe an association between IL-10 genotypes and plasma IL-10 levels in patients with Sjogren's syndrome. A study on patients with H pylori-associated gastritis showed individuals carrying the [rs1800871](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800871) C allele had higher mucosal IL-10 mRNA expression levels \[[@r50]\]. As mentioned above, such studies have not yet been performed in patients with ocular BD and should be addressed in the future. Furthermore, studies should not only be focused on the mRNA expression of IL-10 but they should also deal with functional immunosuppressive properties of the various IL-10 protein variants.

Unexpectedly, the other three SNPs were not found to be associated with BD, and none of the tested SNPs were found to be associated with VKH syndrome. The number of samples in our study seems to be sufficient to ensure the accuracy of our observations. The absence of an IL-10 gene association was also observed in patients with metabolic syndrome in Taiwan \[[@r43]\], as well as in non-Hodgkin's lymphoma patients in the German population \[[@r44]\]. These results indicate there is a significant difference in gene susceptibility among different diseases. The inconsistent result between IL-10 SNPs and susceptibility to VKH syndrome and BD may be partly explained by the different etiology and manifestations of these two uveitis entities. VKH syndrome is mediated by an autoimmune response against melanocytes (autoimmune disease), whereas BD is considered mediated by an aberrant response against invading viruses or microbes (autoinflammatory disease) \[[@r51],[@r52]\]. BD is a multisystem inflammatory disorder characterized by recurrent oral ulcerations, genital ulcerations, recurrent uveitis, and multiple skin lesions. VKH syndrome is a multisystem autoimmune disease characterized by bilateral granulomatous panuveitis, poliosis, vitiligo, alopecia, and central nervous system and auditory signs. To avoid confounding factors, including a selection of patients and healthy controls, as well as ethnic factors, in the results of gene susceptibility to disease in a case-control study, we made several efforts to ensure the accuracy of the results. We paid particular attention to the selection of patients with a definite diagnosis and control individuals to ensure they were from the same ethnic background. To ensure a balance in genotype and allele distributions among the tested patients and the controls, the HWE was examined. Direct sequencing was performed in 20% of the total samples, and the results were in complete accordance with the previous genotyping outcomes.

Taken together, our study confirms the role of IL-10 polymorphisms in BD and suggests a lack of endogenous control of inflammation may play an important role in the pathogenesis of this disease.

Conclusion
----------

In conclusion, our study demonstrated rs1800871, rs1800872, and rs1554286 of IL-10 were possibly associated with BD. However, it is unclear whether or how these SNPs play a role in BD. To clarify this issue, further studies should be conducted. Our study found none of the tested six SNPs was associated with VKH syndrome. Considering only six SNPs of the IL-10 gene were tested in this study, it is unclear whether other SNPs of IL-10 are associated with VKH syndrome. Further studies are needed to address this issue.
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